Kawasaki Disease
Kawasaki disease is an acute illness primarily affecting children under 5 that causes inflammation in blood vessels throughout the body, particularly the coronary arteries. Without treatment, up to 25% of affected children develop coronary artery aneurysms. High-dose IVIG given within 10 days of fever onset is the standard of care and dramatically reduces cardiac complications.
You may qualify for clinical trials that provide Gammagard Liquid at no cost
Clinical trials may give you access to this treatment while helping advance medical research
Search TrialsIVIG at 2g/kg as a single infusion is the standard first-line treatment and should be administered within 10 days of fever onset. No step therapy should be required — this is an acute, time-sensitive treatment. For IVIG-refractory cases, a second dose of IVIG or infliximab may be necessary.
Diagnosis not meeting classic Kawasaki criteria (incomplete Kawasaki may be denied)
Very Common
IVIG dose challenged (standard is 2g/kg single infusion)
Common
Treatment requested after the 10-day window
Common
Second IVIG dose denied for refractory cases
Occasional
Infliximab denied as rescue therapy
Occasional
- 1.Document fever duration, clinical findings meeting AHA criteria (even if incomplete Kawasaki)
- 2.Cite AHA guidelines (2017) supporting IVIG within 10 days of illness onset
- 3.For incomplete Kawasaki, include echocardiography findings and laboratory markers (CRP, ESR, albumin)
- 4.For refractory cases requiring a second IVIG dose, document persistent or recurrent fever >36 hours after first dose
- 5.Emphasize urgency — coronary artery aneurysm risk increases with treatment delay
Active clinical trials that may provide treatment at no cost.
Copay cards, patient assistance programs, and foundation grants for this condition's treatments.
Want to know what you'll actually pay?
Estimate your annual out-of-pocket cost with and without assistance programs.
Estimate My CostsDenied for Kawasaki Disease Treatment?
Ellen can decode your denial, find your appeal strategy, and generate your appeal letter — free.